bioequivalence of drug combination [Regulatives / Guidelines]

posted by balakotu – India, 2018-04-13 06:40 (1579 d 16:01 ago) – Posting: # 18675
Views: 1,474

(edited by Ohlbe on 2018-04-13 10:22)

Hello Norah,
As per USFDA, it is mandatory to perform separate studies for separate products.
FDA will not accept plain candesartan ANDA without BE studies.
Moreover, candesartan a BCS class II product and waiver approach (based on combination product BE study) is not possible to get the waiver for plain Candesartan.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

UA Flag
Activity
 Admin contact
22,289 posts in 4,666 threads, 1,585 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Tuesday 22:41 CEST (Europe/Vienna)

The existing scientific concepts cover always only
a very limited part of reality,
and the other part that has not yet
been understood is infinite.    Werner Heisenberg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5